BioPharmSignal logoBioPharmSignal

Biotech News

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

Exelixis (EXEL)ExelixisConference / presentation

– Presentations to be webcast on www.exelixis.com – ALAMEDA, Calif. --(BUSINESS WIRE)--Sep. 1, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Wells Fargo 21 st Annual Healthcare

Related news

KURAKura Oncology2026-09-01 11:15 EST

Kura Oncology to Participate in Three Investor Conferences in September

CHRSCoherus BioSciences, Inc.2026-08-31 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

BCRXBioCryst Pharmaceuticals2026-09-01 11:00 EST

BioCryst to Present at Upcoming Investor Conference

FATEFate Therapeutics2026-09-03 11:00 EST

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

LYELLyell Immunopharma2026-09-14 11:00 EST

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

MGNXMacroGenics2026-09-09 20:05 EST

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

REPLReplimune Group2026-09-03 12:00 EST

Replimune to Present at the Cantor Global Healthcare Conference 2026

LEGNLegend Biotech Corporation2026-09-01 12:00 EST

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

ELVNEnliven Therapeutics2026-08-31 22:05 EST

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

View all latest news

Exelixis

Commercial Oncology Company Exelixis develops and commercializes therapies for genitourinary and gastrointestinal cancers. Revenue from its established cabozantinib franchise funds a broad effort to create additional oncology products and combinations. Cabozantinib Franchise Cabozantinib is the company’s principal commercial asset and is...

Recent company news

EXELExelixis2026-09-01 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

EXELExelixis2026-08-31 18:30 EST

Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

EXELExelixis2026-07-22 20:30 EST

Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

EXELExelixis2026-06-22 12:00 EST

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

Stock data

Close
58.49 USD
Market cap
12.2B USD
Exchange
NASDAQ
Sector
Small Molecule Drugs
Location
United States